A 24-week, randomized, double-blind, parallel-group, placebo-controlled, dose finding, safety, tolerability, and efficacy study of the human anti-IL-12 antibody ABT-874 in subjects with multiple sclerosis with a 24-week double-blind, active extension phase.

Trial Profile

A 24-week, randomized, double-blind, parallel-group, placebo-controlled, dose finding, safety, tolerability, and efficacy study of the human anti-IL-12 antibody ABT-874 in subjects with multiple sclerosis with a 24-week double-blind, active extension phase.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2013

At a glance

  • Drugs Briakinumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2007 Status change from in progress to completed.
    • 09 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top